Nicholls M D, Davies V J, Au-Yeung D, Wedderburn C, Lovric A, Klarkowski D B
Haematology Department, Concord Hospital, NSW.
Med J Aust. 1992 Jul 20;157(2):92-4.
To determine the clinical efficacy of transfusion of frozen-thawed (FT) red cells using a 5-bag system for freezing (at -20 degrees C to -25 degrees C), storage and reconstitution.
A prospective, controlled, non-randomised clinical trial was undertaken with two groups of orthopaedic surgical patients. Nine patients received FT homologous blood and a control group of 10 patients received homologous blood stored in liquid form at 4 degrees C. Five transfusion-dependent patients with medical conditions were also studied.
Thirty-three FT units were transfused without incident to 14 patients. In addition to clinical assessment, haematological and biochemical parameters were monitored after transfusion. There were no clinical side effects and laboratory data were consistent with those after recent surgery or for pre-existing medical conditions and subsequent blood transfusion. On the practical side certain technical difficulties were encountered which improved with experience.
One of the major advantages of the system is the 35-day shelf-life at 4 degrees C after reconstitution. This system has potential for pre-deposit autologous collection, especially where large volume replacement may be required.
确定使用五袋系统进行冷冻（在-20℃至-25℃）、储存和复溶的解冻红细胞输注的临床疗效。
对两组骨科手术患者进行了一项前瞻性、对照、非随机临床试验。9名患者接受了解冻的同源血液，对照组的10名患者接受了4℃液态储存的同源血液。还研究了5名有医疗状况的输血依赖患者。
33个解冻单位的血液顺利输注给了14名患者。除了临床评估外，还在输血后监测了血液学和生化参数。没有临床副作用，实验室数据与近期手术后或原有医疗状况及后续输血后的情况一致。在实际操作方面遇到了一些技术困难，但随着经验的积累有所改善。
该系统的主要优点之一是复溶后在4℃下有35天的保质期。该系统有进行预存自体采血的潜力，特别是在可能需要大量血液替代的情况下。
